The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: A pilot study
Authors:
- Juan A. Garcia-VelascoJGJuan A. Garcia-Velasco
- Luis MorenoLMLuis Moreno
- Alberto PachecoAPAlberto Pacheco
- Alfredo GuillénAGAlfredo Guillén
- Luis DuqueLDLuis Duque
- Antonio RequenaARAntonio Requena
- Antonio PellicerAPAntonio Pellicer
- 1 July 2005
- journal article
- research article
- Published by Elsevier in Fertility and Sterility
- Vol. 84 (1) , 82-87
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Effect of Insulin-Like Growth Factor-I During Preantral Follicular Culture on Steroidogenesis, In Vitro Oocyte Maturation, and Embryo Development in Mice1Biology of Reproduction, 2004
- A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cyclesFertility and Sterility, 2004
- The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrestHuman Reproduction Update, 2004
- Aromatase Inhibitors in Ovulation InductionSeminars in Reproductive Medicine, 2004
- Antagonist/letrozole protocol for patients failing microdose agonist flare stimulationFertility and Sterility, 2002
- Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor respondersFertility and Sterility, 2002
- Androgens stimulate early stages of follicular growth in the primate ovary.Journal of Clinical Investigation, 1998
- Endocrinology: Iminunohistochemical study of steroidogenesis and cell proliferation in polycystic ovarian syndromeHuman Reproduction, 1996
- Mechanistic studies on aromatase and related CC bond cleaving P-450 enzymesThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- 17β‐Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals*Clinical Endocrinology, 1992